Effect of uralipide on acute heart failure

In patients with acute heart failure, early application of vasodilator can reduce the working pressure of cardiovascular wall and reduce the potential myocardial injury, which is beneficial to the recovery of patients. The researchers recently studied the use of uralipide in patients with acute heart failure.

In a double-blind trial, the researchers recruited 2157 patients with acute heart failure to receive either uralipide (15ng / kg / min) or placebo for two days. At the beginning of treatment, the median time of initial clinical review was 6 hours. The key endpoint was a hierarchical composite terminal with negative correlation follow-up of 15 months for cardiovascular death and review of the original two-day clinical process.

The data showed that 236 cardiovascular deaths occurred in uralipide group and 225 cases in placebo group (21.7% vs 21.0%, 95% CI 0.85-1.25, P = 0.75). There was no significant difference in the results of intention to treat between groups. However, there was no significant difference in cardiac troponin T level between the two groups.

The results showed that the use of uralipide in patients with acute heart failure can cause excellent physiological effects, but the short-term treatment will not harm the clinical complex terminal or reduce the long-term cardiovascular mortality rate.

If the original article is reprinted, please indicate the source（ www.gotopbio.com ）”